aspirin has been researched along with s 8932 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Amini, H; Azhdari Tehrani, H; Haji Aghajani, M; Moradi, O; Pourheidar, E; Rabiei, MM; Sistanizad, M | 1 |
Brandt, C; Deinhardt-Emmer, S; Doshi, H; Ehrhardt, C; Giebeler, L; Häring, C; Jungwirth, J; König, S; Löffler, B | 1 |
3 other study(ies) available for aspirin and s 8932
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary Artery Disease; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Disseminated Intravascular Coagulation; Drug Combinations; Female; Hospital Mortality; Humans; Hypertension; Iran; Lopinavir; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Pulmonary Embolism; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2021 |
D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aspirin; COVID-19 Drug Treatment; Glycine; Humans; Lysine; SARS-CoV-2 | 2022 |